Enovis Corp (ENOV)vsNovartis AG ADR (NVS)
ENOV
Enovis Corp
$19.28
+4.73%
HEALTHCARE · Cap: $1.07B
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2369% more annual revenue ($56.69B vs $2.30B). NVS leads profitability with a 22.5% profit margin vs -48.0%. ENOV appears more attractively valued with a PEG of 1.90. ENOV earns a higher WallStSmart Score of 55/100 (C).
ENOV
Buy55
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.6%
Fair Value
$34.86
Current Price
$19.28
$15.58 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 153.1% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Expensive relative to growth rate
3.2% revenue growth
Smaller company, higher risk/reward
Operating margin of 4.2%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ENOV
The strongest argument for ENOV centers on Price/Book, EPS Growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : ENOV
The primary concerns for ENOV are PEG Ratio, Revenue Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
ENOV profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
ENOV carries more volatility with a beta of 1.43 — expect wider price swings.
ENOV is growing revenue faster at 3.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
ENOV scores higher overall (55/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enovis Corp
HEALTHCARE · MEDICAL DEVICES · USA
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?